Common mechanisms involved in Alzheimer's disease and type 2 diabetes: A key role of chronic bacterial infection and inflammation

Aging

Volumn 8, Issue 4, 2016, Pages 575-588

  Miklossy, Judith ^a   McGeer, Patrick L ^b  

^a Alzheimer Research Center Prevention Alzheimer International Foundation   (Switzerland)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Chlamydia pneumoniae; Diabetes type 2; Helicobacter pylori; Infection; Inflammation; Spirochetes

Indexed keywords

ALZHEIMER DISEASE; BACTERIAL INFECTION; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HUMAN; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ALZHEIMER DISEASE; BACTERIAL INFECTIONS; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION;

EID: 84978267818     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100921     Document Type: Review

References (201)

1. Voisin T, Lugardon S, Balardy L, Vellas B. Vascular risk factors and Alzheimer's disease. Rev Med Interne. 2003; 24 Suppl 3:288s-291s
2. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996; 39:1392-1397
3. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004; 53:474-481
4. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53:1937-1942
5. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 1997; 826:422-427
6. Grodstein F, Chen J, Wilson RS, Manson JE. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care 2001; 24:1060-1065
7. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002; 51:1256-1262
8. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004; 61:661-666
9. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology. 2004; 63:1181-1186
10. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T. et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 1997; 315:1045-1049
11. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003: 100:4162-4167
12. Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem. 2000; 275:36621-36625
13. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL. et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry. 2009;14:469-486
14. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1:1311-1315
15. Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P.Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun. 1997; 65:4832-4835
16. Saikku P. Epidemiology of Chlamydia pneumoniae in atherosclerosis. Am Heart J. 1999; 138:S500-503
17. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994; 71:437-439
18. Martin-de-Argila C, Boixeda D, Canton R, Gisbert JP, Fuertes A. High seroprevalence of Helicobacter pylori infection in coronary heart disease. Lancet. 1995; 346:310
19. Renvert S, Pettersson T, Ohlsson O, Persson GR. Bacterial profile and burden of periodontal infection in subjects with a diagnosis of acute coronary syndrome. J Periodontol. 2006; 77:1110-1119
20. Zaremba M, Gorska R, Suwalski P, Kowalski J. Evaluation of the incidence of periodontitis-associated bacteria in the atherosclerotic plaque of coronary blood vessels. J Periodontol. 2007; 78:322-327
21. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am Heart J. 1999; 138:S534-536
22. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol. 2000; 71:1554-1560
23. Rassu M, Cazzavillan S, Scagnelli M, Peron A, Bevilacqua PA, Facco M. et al. Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions. Atherosclerosis. 2001; 158:73-79
24. Martin RJ. Infections and asthma. Clin Chest Med. 2006; 27:87-98
25. MacDowell AL, Bacharier LB. Infectious triggers of asthma. Immunol Allergy Clin North Am. 2005; 25:45-66
26. Micillo E, Bianco A, D'Auria D, Mazzarella G, Abbate GF. Respiratory infections and asthma. Allergy. 2000; 55 Suppl 61:42-45
27. Miklossy J, Martins R, Darbinian N, Khalili K, McGeer P. Type 2 diabetes: Local Inflammation and Direct Effect of Bacterial Toxic Components. Open Pathol J 2008, 2:86-95
28. Miklossy J: Alzheimer's disease-a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation 2011, 8(1):90
29. Miklossy J: Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med. 2011; 13:e30
30. DeGraba TJ. Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke. 2004; 35S:2712-2719
31. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48:1038-1050
32. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol. 2001; 58:1790-1792
33. Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M, de Leon MJ. Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. J Alzheimer's Dis. 2008; 13:437-449
34. Santacroce L, Carlaio RG, Bottalico L. Does it make sense that diabetes is reciprocally associated with periodontal disease? Endocr Metab Immune Disord Drug Targets. 2010; 10:57-70
35. Seppaa B, Ainamo J. Dark field microscopy of the subgingival microflora in insulin-dependent diabetics. J Clin Periodontol. 1996; 23:63-67
36. Ling LJ, Ho CC, Wu CY, Chen YT, Hung SL. Association between human herpesviruses and the severity of periodontitis. J Periodontol. 2004, 75:1479-1485
37. Heydenrijk K, Meijer HJ, van der Reijden WA, Raghoebar GM, Vissink A, Stegenga B. Microbiota around root-form endosseous implants: a review of the literature. Int J Oral Maxillofac Implants. 2002; 17:829-838
38. O'Brien-Simpson NM, Veith PD, Dashper SG, Reynolds EC. Antigens of bacteria associated with periodontitis. Periodontol 2000 2004;35:101-134
39. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B et al. The Alzheimer's disease-associated amyloid betaprotein is an antimicrobial peptide. PLoS One 2010; 5:e9505
40. Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer's betaamyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem. 2000; 275:14077-14083
41. Wang L, Liu Q, Chen JC, Cui YX, Zhou B, Chen YX. et al. Antimicrobial activity of human islet amyloid polypeptides: an insight into amyloid peptides' connection with antimicrobial peptides. Biol Chem. 2012; 393:641-646
42. Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel) 2014; 7:545-594
43. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung. 1971; 19:1-8
44. Braak H, Braak E, Grundke-Iqbal I, Iqbal K: Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett. 1986; 65:351-355
45. Markesbery WR, Wang HZ, Kowall NW, Kosik KS, McKee AC. Morphometric image analysis of neuropil threads in Alzheimer's disease. Neurobiol Aging. 1993; 14:303-307
46. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984; 120:885-890
47. Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol. 1984; 2:357-369
48. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987, 325:733-736
49. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985; 82:4245-4249
50. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998; 8:447-453
51. Monning U, Konig G, Prior R, Mechler H, Schreiter-Gasser U, Masters CL. et al. Synthesis and secretion of Alzheimer amyloid beta A4 precursor protein by stimulated human peripheral blood leucocytes. FEBS Lett. 1990; 277:261-266
52. Allen JS, Murphy GM, Jr., Eng LF, Stultz KE, Davies HD, Pickford LB. et al. Alzheimer's disease: beta-amyloid precursor protein mRNA expression in mononuclear blood cells. Neurosci Lett. 1991; 132:109-112
53. Ledoux S, Rebai N, Dagenais A, Shaw IT, Nalbantoglu J, Sekaly RP. et al. Amyloid precursor protein in peripheral mononuclear cells is up-regulated with cell activation. J Immunol. 1993; 150:5566-5575
54. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 1992, 42:447-449
55. Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M. et al. Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging. 1996; 17:681-686
56. McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol. 2002; 8:529-538
57. McGeer PL, McGeer EG. The possible role of complement activation in Alzheimer disease. Trends Mol Med. 2002; 8:519-523
58. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987; 79:195-200
59. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ. et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989; 86:7611-7615
60. Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol. 2002; 17:113-118
61. Balin BJ, Little CS, Hammond CJ, Appelt DM, Whittum-Hudson JA, Gerard HC. et al. Chlamydophila pneumoniae and the etiology of late-onset Alzheimer's disease. J Alzheimers Dis. 2008; 13:371-380
62. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer's disease: the enemy within. J Alzheimer's Dis. 2008; 13:393-405
63. Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J Alzheimer's Dis. 2013; 36:665-677
64. Kountouras J, Tsolaki M, Gavalas E, Boziki M, Zavos C, Karatzoglou P. et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 2006; 66:938-940
65. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care. 2004; 27:1047-1053
66. Matthews DR, Matthews PC. Banting Memorial Lecture 2010 Type 2 diabetes as an 'infectious' disease: is this the Black Death of the 21st century? Diabet Med. 2011; 28:2-9
67. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000 Clin Ther. 2003; 25:1017-1038
68. Lopes DH, Colin C, Degaki TL, de Sousa AC, Vieira MN, Sebollela A, Martinez AM, Bloch C, Jr., Ferreira ST, Sogayar MC. Amyloidogenicity and cytotoxicity of recombinant mature human islet amyloid polypeptide (rhIAPP). J Biol Chem. 2004; 279:42803-42810
69. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987; 84:8628-8632
70. Cooper GJ, Willis AC, Reid KB, Clark A, Baker CA, Turner RC. et al. Diabetes-associated peptide. Lancet. 1987; 2:966
71. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol. 1987; 127:414-417
72. Sanke T, Bell GI, Sample C, Rubenstein AH, Steiner DF. An islet amyloid peptide is derived from an 89-amino acid precursor by proteolytic processing. J Biol Chem. 1988; 263:17243-17246
73. Cooper GJ, Leighton B, Dimitriadis GD, Parry-Billings M, Kowalchuk JM, Howland K et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci U S A. 1988, 85:7763-7766
74. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab. 2004, 89:3629-3643
75. Miragliotta G, Del Prete R, Mosca A. Helicobacter pylori infection and coronary heart disease. Lancet. 1994; 344:751
76. Klegeris A, McGeer PL. Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. Biochem Biophys Res Commun. 2007; 357:1096-1099
77. Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ. et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009; 29:9078-9089
78. Brauner A, Carlsson B, Sundkvist G, Ostenson CG. Falsepositive treponemal serology in patients with diabetes mellitus. J Diabetes. Complications 1994, 8:57-62
79. Vanier MT, Neuville P, Michalik L, Launay JF. Expression of specific tau exons in normal and tumoral pancreatic acinar cells. J Cell Sci. 1998; 111 :1419-1432
80. Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F et al. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. Mol Cancer Ther. 2007; 6:1509-1516
81. Michalik L, Neuville P, Vanier MT, Launay JF. Pancreatic tau related maps: biochemical and immunofluorescence analysis in a tumoral cell line. Mol Cell Biochem. 1995; 143:107-112
82. Miklossy J, Qing H, Radenovic A, Kis A, Vileno B, Laszlo F. et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging. 2010; 31:1503-1515
83. Maj M, Gartner W, Ilhan A, Neziri D, Attems J, Wagner L. Expression of TAU in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. J Endocrinol. 2010; 205:25-36
84. Gunton JE, Kulkarni RN, Yim S, Okada T, Hawthorne WJ, Tseng YH. et al. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell. 2005; 122:337-349
85. Charge SB, Esiri MM, Bethune CA, Hansen BC, Clark A. Apolipoprotein E is associated with islet amyloid and other amyloidoses: implications for Alzheimer's disease. J Pathol. 1996; 179:443-447
86. Miklossy J, Taddei K, Martins R, Escher G, Kraftsik R, Pillevuit O. et al. Alzheimer disease: curly fibers and tangles in organs other than brain. J Neuropathol Exp Neurol. 1999; 58:803-814
87. Choo LP, Wetzel DL, Halliday WC, Jackson M, LeVine SM, Mantsch HH. In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. Biophys J. 1996; 71:1672-1679
88. Miklossy J, Kis A, Radenovic A, Miller L, Forro L, Martins R. et al. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging. 2006; 27:228-236
89. Rosenbloom J: The relation between diabetes mellitus and clinical syphilis. JAMA. 1917; 68:1232-1234
90. Warthin A, Wilson, F. The Coincidence of Latent Syphilis and Diabetes. Am J Med Sci. 1916; 152:157-164
91. Fukuchi K, Hart M, Yan Z, Hassell JR, Li L. Transgenic mice overexpressing both amyloid beta-protein and perlecan in pancreatic acinar cells. Histol Histopathol. 2004; 19:845-852
92. Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ. A liposome-based therapeutic vaccine against beta-amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci U S A. 2002; 99:2332-2337
93. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes. 2007; 56:1817-1824
94. Gong W, Liu ZH, Zeng CH, Peng A, Chen HP, Zhou H. et al. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int. 2007; 72:213-218
95. Jackson K, Barisone GA, Diaz E, Jin LW, DeCarli C, Despa F. Amylin deposition in the brain: A second amyloid in Alzheimer disease? Annals of neurology. 2013; 74:517-526
96. Beaumont K, Kenney MA, Young AA, Rink TJ. High affinity amylin binding sites in rat brain. Mol Pharmacol. 1993; 44:493-497
97. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40:1286-1292
98. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998; 41:1241-1248
99. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S. et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999; 353:1649-1652
100. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1999; 22:767-772
101. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. Creactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327-334
102. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004; 27:813-823
103. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53:693-700
104. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003; 52:812-817
105. Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M. et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003; 163:93-99
106. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C. et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes. 2005; 54:2932-2938
107. Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K. et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care. 2005; 28:2497-2500
108. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003; 26:2754-2757
109. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004; 110:380-385
110. Festa A, D'Agostino R, Jr., Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51:1131-1137
111. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda). 2009; 24:325-331
112. Boni-Schnetzler M, Thorne J, Parnaud G, Marselli L, Ehses JA, Kerr-Conte J. et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta-cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008; 93:4065-4074
113. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. Islet-associated macrophages in type 2 diabetes. Diabetologia. 2009; 52:1686-1688
114. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R. et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007; 56:2356-2370
115. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch Physiol Biochem. 2009; 115:240-247
116. Cecil RL. Text-book of Medicine. Saunders company, Philadelphia and London, 4th edition, 1938:pp1614
117. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia. 2009; 52:1665-1668
118. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292:E740-747
119. Pussinen PJ, Havulinna AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. 2011; 34:392-397
120. Nigam P, Dayal SG, Srivastava P, Joshi LD, Goyal BM, Dutt B. et al. Diabetic status in leprosy. Hansenol Int. 1979; 4:7-14
121. Restrepo BI. Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin Infect Dis. 2007; 45:436-438
122. Perez A, Brown HS, 3rd, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg. 2006; 74:604-611
123. Maalej S, Belhaoui N, Bourguiba M, Mahouachi R, Chtourou A, Taktak S. et al. [Pulmonary tuberculosis and diabetes. A retrospective study of 60 patients in Tunisia]. Presse medicale. 2009; 38:20-24
124. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rahbar MH. et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Inf Dis. 2008; 40:888-893
125. Price FW. Textbook of the Practice of Medicine. Oxford Medical Publication, Humphrey Milford Publisher, Oxford University Press, London and Edinburgh, 6th edition, 1941:pp 2032
126. Stevenson CR, Critchley JA, Forouhi NG, Roglic G, Williams BG, Dye C. et al. Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn. 2007; 3:228-245
127. Dixon B. Diabetes and tuberculosis: an unhealthy partnership. Lancet Infect Dis. 2007; 7:444
128. van der Werf N, Kroese FG, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev. 2007; 23:169-183
129. Goldberg E, Krause I. Infection and type 1 diabetes mellitus-a two edged sword? Autoimmun Rev. 2009; 8:682-686
130. Avasthi TS, Ahmed N. Helicobacter pylori and type 1 diabetes mellitus: possibility of modifying chronic disease susceptibility with vaccinomics at the anvil. Omics. 2011; 15:589-596
131. Toplak H, Haller EM, Lauermann T, Weber K, Bahadori B, Reisinger EC. et al. Increased prevalence of IgA-Chlamydia antibodies in NIDDM patients. Diabetes Res Clin Pract. 1996; 32:97-101
132. Wang C, Gao D, Kaltenboeck B. Acute Chlamydia pneumoniae reinfection accelerates the development of insulin resistance and diabetes in obese C57BL/6 mice. J Inf Dis. 2009; 200:279-287
133. Nishihara R, Sugano N, Takano M, Shimada T, Tanaka H, Oka S. et al. The effect of Porphyromonas gingivalis infection on cytokine levels in type 2 diabetic mice. J Periodontal Res. 2009; 44:305-310
134. Kozak R, Juhasz E, Horvat G, Harcsa E, Lovei L, Sike R, Szele K: [Helicobacter pylori infection in diabetic patients]. Orv Hetil. 1999; 14:993-995
135. Quatrini M, Boarino V, Ghidoni A, Baldassarri AR, Bianchi PA, Bardella MT. Helicobacter pylori prevalence in patients with diabetes and its relationship to dyspeptic symptoms. J Clin Gastroenterol. 2001; 32:215-217
136. Gulcelik NE, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M.et al. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest. 2005; 28:214-217
137. Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol. WJG. 2009; 15:2701-2707
138. Quadri R, Rossi C, Catalfamo E, Masoero G, Lombardo L, Della Monica P. et al. Helicobacter pylori infection in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2000; 10:263-266
139. Ohnishi M, Fukui M, Ishikawa T, Ohnishi N, Ishigami N, Yoshioka K. et al. Helicobacter pylori infection and arterial stiffness in patients with type 2 diabetes mellitus. Metabolism. 2008; 57:1760-1764
140. Hamed SA, Amine NF, Galal GM, Helal SR, Tag El-Din LM, Shawky OA. et al. Vascular risks and complications in diabetes mellitus: the role of helicobacter pylori infection. J Stroke Cerebrovasc Dis. 2008; 17:86-94
141. Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usmani MA. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol. 2007; 18:225-229
142. Perdichizzi G, Bottari M, Pallio S, Fera MT, Carbone M, Barresi G. Gastric infection by Helicobacter pylori and antral gastritis in hyperglycemic obese and in diabetic subjects. New Microbiol. 1996; 19:149-154
143. Oldenburg B, Diepersloot RJ, Hoekstra JB. High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci.1996; 41:458-461
144. Han X, Li Y, Wang J, Liu B, Hu H, Li X. et al. Helicobacter pylori infection is associated with type 2 diabetes among a middle-and old-age Chinese population. Diabetes Metab Res Rev. 2015
145. Roubaud Baudron C, Franceschi F, Salles N, Gasbarrini A. Extragastric diseases and Helicobacter pylori. Helicobacter. 2013; 18 Suppl 1:44-51
146. Pellicano R, Astegiano M, Rizzetto M. Helicobacter pylori and type 2 diabetes mellitus. Negative results and goals of future studies. Saudi Med J. 2008; 29:1213
147. Demir M, Gokturk HS, Ozturk NA, Kulaksizoglu M, Serin E, Yilmaz U. Helicobacter pylori prevalence in diabetes mellitus patients with dyspeptic symptoms and its relationship to glycemic control and late complications. Dig Dis Sci. 2008; 53:2646-2649
148. Ko GT, Chan FK, Chan WB, Sung JJ, Tsoi CL, To KF. et al. Helicobacter pylori infection in Chinese subjects with type 2 diabetes. Endocr Res. 2001; 27:171-177
149. Hughes MK, Fusillo MH, Roberson BS: Positive fluorescent treponemal antibody reactions in diabetes. Appl Microbiol. 1970; 19:425-428
150. Bjerkhoel A, Carlsson M, Ohlsson J: Peripheral facial palsy caused by the Borrelia spirochete. Acta Otolaryngol. 1989; 108:424-430
151. Fenesy KE. Periodontal disease: an overview for physicians. Mt Sinai J Med. 1998; 65:362-369
152. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. Ann Periodontol. 1998; 3:51-61
153. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005; 366:1809-1820
154. Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. Ann Periodontol. 2001, 6:99-112
155. Gurav A, Jadhav V. Periodontitis and risk of diabetes mellitus. J Diabetes. 2011; 3:21-28
156. Mealey BL, Rose LF. Diabetes mellitus and inflammatory periodontal diseases. Curr Opin Endocrinol Diabetes Obes. 2008; 15:135-141
157. Meurman JH, Hamalainen P. Oral health and morbidity-implications of oral infections on the elderly. Gerodontology. 2006; 23:3-16
158. Loe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care. 1993; 16:329-334
159. Nelson RG, Shlossman M, Budding LM, Pettitt DJ, Saad MF, Genco RJ. et al. Periodontal disease and NIDDM in Pima Indians. Diabetes Care. 1990; 13:836-840
160. Emrich LJ, Shlossman M, Genco RJ. Periodontal disease in non-insulin-dependent diabetes mellitus. J periodontology. 1991; 62:123-131
161. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M, Knowler WC. et al. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. Journal of periodontology. 1998; 69:76-83
162. Hintao J, Teanpaisan R, Chongsuvivatwong V, Ratarasan C, Dahlen G. The microbiological profiles of saliva, supragingival and subgingival plaque and dental caries in adults with and without type 2 diabetes mellitus. Oral Microbiol Immunol. 2007; 22:175-181
163. Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG. et al. Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol. 1997; 68:713-719
164. de Luis DA, Garcia Avello A, Lasuncion MA, Aller R, Martin de Argila C, Boixeda de Miquel D. et al. Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. Clin Nutr. 1999; 18:227-231
165. Erridge C. Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. Atherosclerosis. 2011; 216:1-6
166. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006; 124:783-801
167. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Ann Rev Immunol. 2009; 27:229-265
168. Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol. 2009; 21:242-253
169. Lien E, Ingalls RR: Toll-like receptors. Crit Care Med. 2002; 30S:S1-11
170. Vives-Pi M, Somoza N, Fernandez-Alvarez J, Vargas F, Caro P, Alba A. et al. Evidence of expression of endotoxin receptors CD14, toll-like receptors TLR4 and TLR2 and associated molecule MD-2 and of sensitivity to endotoxin (LPS) in islet beta cells. Clin Exp Immunology. 2003; 133:208-218
171. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT, Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002; 418:291
172. Suh YH, Chong YH, Kim SH, Choi W, Min K, Jeong SJ. et al. Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP). Ann N Y Acad Sci. 1996; 786:169-183
173. Kobayashi N, Masuda J, Kudoh J, Shimizu N, Yoshida T. Binding sites on tau proteins as components for antimicrobial peptides. Biocontrol Sci. 2008; 13:49-56
174. Hirakura Y, Carreras I, Sipe JD, Kagan BL. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid. 2002; 9:13-23
175. Anguiano M, Nowak RJ, Lansbury PT, Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a porelike mechanism that may be relevant to type II diabetes. Biochemistry. 2002; 41:11338-11343
176. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE. et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem. 2004, 279:46363-46366
177. Hirakura Y, Yiu WW, Yamamoto A, Kagan BL. Amyloid peptide channels: blockade by zinc and inhibition by Congo red (amyloid channel block). Amyloid. 2000; 7:194-199
178. Kagan BL, Thundimadathil J. Amyloid peptide pores and the beta sheet conformation. Adv Exp Med Biol. 2010; 677:150-167
179. Gekara NO, Westphal K, Ma B, Rohde M, Groebe L, Weiss S. The multiple mechanisms of Ca2+ signalling by listeriolysin O, the cholesterol-dependent cytolysin of Listeria monocytogenes. Cell Microbiol. 2007; 9:2008-2021
180. Gonzalez MR, Bischofberger M, Pernot L, van der Goot FG, Freche B. Bacterial pore-forming toxins: the (w)hole story? Cell Mol Life Sci. 2008; 65:493-507
181. Gekara NO, Weiss S. Lipid rafts clustering and signalling by listeriolysin O. Biochem Soc Trans. 2004; 32:712-714
182. Cossart P, Lecuit M. Interactions of Listeria monocytogenes with mammalian cells during entry and actin-based movement: bacterial factors, cellular ligands and signaling. EMBO J. 1998; 17:3797-3806
183. Kayal S, Lilienbaum A, Poyart C, Memet S, Israel A, Berche P. Listeriolysin O-dependent activation of endothelial cells during infection with Listeria monocytogenes: activation of NFkappa B and upregulation of adhesion molecules and chemokines. Mol Microbiol. 1999; 31:1709-1722
184. Hamon MA, Batsche E, Regnault B, Tham TN, Seveau S, Muchardt C, Cossart P. Histone modifications induced by a family of bacterial toxins. Proc Natl Acad Sci U S A. 2007; 104:13467-13472
185. Kim W, Hecht MH. Sequence determinants of enhanced amyloidogenicity of Alzheimer A(beta)42 peptide relative to A(beta)40. J Biol Chem. 2005; 280:35069-35076
186. Otzen D, Nielsen PH. We find them here, we find them there: functional bacterial amyloid. Cell Mol Life Sci. 2008; 65:910-927
187. Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M. et al. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science. 2002; 295:851-855
188. Larsen P, Nielsen JL, Dueholm MS, Wetzel R, Otzen D, Nielsen PH. Amyloid adhesins are abundant in natural biofilms. Environ Microbiol. 2007; 9:3077-3090
189. Jordal PB, Dueholm MS, Larsen P, Petersen SV, Enghild JJ, Christiansen G. et al. Widespread abundance of functional bacterial amyloid in mycolata and other gram-positive bacteria. Appl Environ Microbiol. 2009; 75:4101-4110
190. Wang X, Hammer ND, Chapman MR. The molecular basis of functional bacterial amyloid polymerization and nucleation. J Biol Chem. 2008; 283:21530-21539
191. Yoshiike Y, Kayed R, Milton SC, Takashima A, Glabe CG. Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromolecular Med. 2007; 9:270-275
192. Roy S, McGuire W, Mascie-Taylor CG, Saha B, Hazra SK, Hill AV. et al. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis. 1997; 176:530-532
193. Knight JC, Kwiatkowski D. Inherited variability of tumor necrosis factor production and susceptibility to infectious disease. Proc Assoc Am Physicians. 1999; 111:290-298
194. Shaw MA, Donaldson IJ, Collins A, Peacock CS, Lins-Lainson Z, Shaw JJ. et al. Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes Immun. 2001; 2:196-204
195. Lagrange PH, Abel L. [The genetic susceptibility to leprosy in humans]. Acta Leprol. 1996; 10:11-27
196. Pacheco e Silva AC. Localisation du Treponema Pallidum dans le cerveau des paralytiques généraux. Revista de Neurologia. 1926; 2:558-565
197. Miklossy J. Biology and neuropathology of dementia in syphilis and Lyme disease. Handb Clin Neurol. 2008; 89:825-844
198. Miklossy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L,. et al. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis. 2004; 6:639-649; discussion 673-681
199. Pacheco e Silva AC. Espirochetose dos centros nervos. Memorias do hospicio de Juquery, anno III-IV 3-4, 1926-27:1-27
200. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging. 1988, 9: 339-349
201. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989; 107:341-346